Core Viewpoint - The announcement by TianKang regarding the approval of a Phase II clinical trial for CKBA cream in treating non-segmental vitiligo in children aged 2-12 is a significant development, potentially positioning CKBA as the first targeted therapy for this condition in children, addressing a gap in treatment options [2]. Group 1 - TianKang's subsidiary, Jiangsu BoChuangYuan Biopharmaceutical Technology Co., Ltd., received a notice from the National Medical Products Administration approving the application for a Phase II clinical study [2]. - The clinical trial will assess the safety, efficacy, and pharmacokinetic characteristics of CKBA cream combined with narrowband ultraviolet B in children with non-segmental vitiligo [2]. - Following the approval, the company plans to expedite the Phase II clinical trial for pediatric vitiligo, indicating a strong commitment to advancing this innovative treatment [2].
泰恩康CKBA乳膏申报儿童白癜风临床试验取得受理通知书